RecruitingPhase 2NCT04861064

Weekly Sirolimus Therapy

Weekly Sirolimus Therapy for the Treatment of Venous and Lymphatic Malformations


Sponsor

Medical University of South Carolina

Enrollment

24 participants

Start Date

Jan 18, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

In current practice, options for venous and lymphatic malformations remain limited. Recently an oral medication, sirolimus, has been found to benefit patients when taken once or twice a day for several months. Unfortunately there are many side effects associated with this medication, some of which can be severe including, neutropenia, oral ulcerations, and lab abnormalities. The purpose of this study is to determine if once weekly dosed sirolimus will be effective for the treatment of venous and lymphatic malformations. Additionally, the study will evaluate patient satisfaction and identify adverse effects. Participants will be on the medication for 6 months with an option to continue after this time period.


Eligibility

Min Age: 2 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Sirolimus for people with lymphatic malformation and venous malformation. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSirolimus

Participants will get Sirolimus (1.5-2 2mg/m2) weekly for 6 months.


Locations(1)

Medical University of South Carolina

Charleston, South Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04861064


Related Trials